SecBot SecBot

CGEN drug pipeline

COMPUGEN LTD · 1 rated drug
$2.04
−2.9% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 1/2
Time to marketAt least 3-5 years. COM701 is in Phase 1/2 (MAIA trial); even with positive interim data in Q1 2027, a registrational Phase 3 trial and FDA review would follow, putting potential approval in the 2029-2031 timeframe.

COM701 anti-PVRIG monoclonal antibody Updated Aug 27

What to watch

The next hard catalyst for COM701 is the MAIA-ovarian interim PFS analysis expected by Q1 2027, roughly 4-6 months out. Positive data could drive a significant re-rating given the strong analyst consensus (10 Buy/Strong Buy vs 1 Hold) and ~41% implied upside to the $4.60 mean price target. Negative data would be a major setback for Compugen's wholly-owned pipeline. Monitor for any pre-announcements or delays.

Bull case
  • COM701 targets a novel immune checkpoint (PVRIG) with a differentiated mechanism, potentially active in tumors resistant to PD-1 inhibitors.
  • Strong analyst conviction: 10 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $4.60 (40.8% upside from $2.84).
  • Cash runway into 2029 ($125.3M, no debt) eliminates near-term financing risk and allows the MAIA trial to reach its readout.
Bear case
  • MAIA-ovarian interim PFS data (expected Q1 2027) could miss efficacy endpoints, wiping out the value of Compugen's wholly-owned lead asset.
  • Elevated short-volume ratio (48-65% range over the past 90 days) indicates persistent bearish positioning and skepticism about the pipeline.
  • Compugen has a $100M ATM facility that could dilute shareholders if cash burn accelerates before the COM701 readout.